Leadership Tigran Abramyan
Ph.D.Principal Scientist, Computational Drug Design
Tigran Abramyan is Principal Scientist at Deep Origin, where he contributes to product development workflows and testing, partnership programs, and internal discovery efforts. He previously led computational chemistry at Totus Medicines, focusing on protein target triaging for covalent DEL and data processing, and at Atomwise performed ultra-large-scale virtual screening and hit expansion across academic, industry, and internal programs. His postdoc was at UNC Eshelman School of Pharmacy on multidisciplinary drug discovery projects. Across these roles, he has advanced discovery in epigenetic targets, immuno-oncology, rare diseases, infectious diseases, remaining agnostic to protein target or modality and applying techniques such as docking, MD/FEP, enhanced sampling, pharmacophore modeling, cheminformatics, and AI/ML-driven design. He holds a PhD in Bioengineering from Clemson University, an MSc in Drug Discovery from University College London, and a Doctor of Pharmacy from First Moscow State Medical University.
Featured Publications
- Cluster analysis of molecular simulation trajectories for systems where both conformation and orientation of the sampled states are important
- Off-Pocket Activity Cliffs: A Puzzling Facet of Molecular Recognition
- Discovery of selective activators of PRC2 mutant EED-I363M
- A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization
- AI is a viable alternative to high throughput screening: a 318-target study
- Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945